CAR T cells targeting abnormal N-glycans for the treatment of refractory/metastatic solid cancers
Grant Award Details
Grant Type:
Grant Number:
DISC2-13507
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$1,414,800
Status:
Active
Grant Application Details
Application Title:
CAR T cells targeting abnormal N-glycans for the treatment of refractory/metastatic solid cancers
Public Abstract:
Research Objective
Develop genetically modified chimeric antigen receptor T cells to kill incurable solid cancers by targeting a previously un-targetable tumor associated carbohydrate antigen.
Impact
Refractory/metastatic solid cancers are almost always incurable and have limited therapeutic options. Directing the immune system to kill cancer cells provides an unprecedented new approach.
Major Proposed Activities
Develop genetically modified chimeric antigen receptor T cells to kill incurable solid cancers by targeting a previously un-targetable tumor associated carbohydrate antigen.
Impact
Refractory/metastatic solid cancers are almost always incurable and have limited therapeutic options. Directing the immune system to kill cancer cells provides an unprecedented new approach.
Major Proposed Activities
- Engineer and optimize a genetically modified chimeric antigen receptor T cell that targets a tumor associated carbohydrate antigen with high sensitivity and specificity.
- Confirm the ability of the engineered CAR-T cells to kill diverse solid cancer cells.
- Assess the ability of the engineered CAR-T cells to kill glioblastoma cells, a highly deadly brain cancer.
- Assess the risk of toxicity to normal tissue from the engineered CAR-T cells.
Statement of Benefit to California:
The citizens of California will benefit from this proposal through development of a new and potent therapy for relapsed/metastatic solid cancers that are incurable and lack effective therapies. The California economy will also benefit from this project through creation and maintenance of bio-tech jobs and the potential to export the therapy worldwide. This project will also further California's international reputation as a global leader in innovation and bio-tech.